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Quetiapine is occasionally associated with cardiovascular adverse effects such as QTc prolongation. QTc prolongation is a side
effect that requires monitoring in order to avoid more serious cardiac complications. One particular understudied area is the
potential for antipsychotics to elicit electroconduction abnormalities in patients with Wolff-Parkinson-White (WPW)
Syndrome. In the present report, we describe a case of quetiapine overdose in a patient with WPW.
1. Introduction
Wolff-Parkinson-White (WPW) Syndrome is a cardiac con-
dition deviation characterized by an accessory pathway that
bypasses the atrioventricular (AV) node resulting in abnor-
mally fast ventricular contractions. Specific electrocardio-
gram (EKG) findings of WPW include delta wave, widened
QRS complex (>110ms), shortened PR interval (<120ms),
and inverted T waves [1]. Although generally asymptomatic
[2], the most common clinical symptom is “palpitations of
the heart [3].” In rare, severe cases, WPW has been linked
to Torsades de pointes and sudden cardiac death [4]. While
the pathophysiology of WPW is well established and studied,
the effects of antipsychotics on patients with WPW remain
unknown.
Other cardiac consequences of antipsychotic medications
have been well characterized, including QTc prolongation
[5]. Specifically, quetiapine is well known to have QTc
prolonging effects and has been linked to dangerous condi-
tions such as Torsades de pointes [6]. However, the potential
effects of quetiapine on patients with WPW have not been
described. Therefore, here, we report the consequences of a
quetiapine overdose in a patient with WPW.
2. Case Report
A 30-year-old female with a past medical history significant
forWPW and a psychiatric history of major depressive disor-
der, posttraumatic stress disorder, borderline personality dis-
order, and several suicide attempts presented to the
Emergency Department (ED) with complaints of decreased
energy, swollen lymph nodes, weight loss (approximately
13.5 kg), and mild abdominal pain. Subsequent interviews
revealed that while waiting for the results of her evaluation,
the patient overdosed on 1200mg of trazodone, 1200mg of
quetiapine, and 900mg of venlafaxine, as a suicide attempt.
Two hours postoverdose, the patient began to exhibit a pro-
longed QTc interval of 486ms which contrasted with her
QTc baseline of 445ms (Figure 1). Of note, no delta wave
was appreciated in the EKG. Her PR interval was 160ms at
baseline and 146ms 2 hrs after (Table 1). Baseline blood pres-
sure was noted at 114/70, but 2 hours postoverdose, the
patient developed hypotension of 86/45mmHg. In addition,
the patient complained of palpitations with a heart rate rang-
ing from 83 to 97. All psychiatric medications were discon-
tinued, and intravenous fluids were provided. Forty-eight
hours after discontinuation of her medication, the patient’s
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EKG normalized including her QTc interval (QT/QTc of
414/434) (Figure 1), and her PR interval was at 160ms
(Table 1). At this point, the patient was medically cleared
and transferred to our inpatient unit.
On the inpatient unit, the patient was slowly reintro-
duced to her psychiatric medications. On day 1, the patient
was started on quetiapine 100mg at bedtime, trazodone
100mg at bedtime, and venlafaxine 150mg in the morning.
This was gradually raised to a maximum dose of quetia-
pine100 mg in am and 300mg at bedtime. Venlafaxine was
increased to 225mg daily and trazodone remained at
100mg at bedtime. Apart from mild sedation, the patient
reported no symptoms or side effects from medications such
as sensation of rapid, fluttering, or pounding heartbeats (pal-
pitations); dizziness or lightheadedness; or shortness of
breath. The patient was discharged after 11 days of inpatient
psychiatric treatment.
After discharge, maintenance treatment consisted of
300mg of quetiapine, 100mg of trazodone, and 225mg of
venlafaxine. A year later, the patient was seen in the ED for
chest palpitations, pain, and dizziness. Her initial EKG was
significant for heart rate of 109 beats per minute, QTc of
450ms, and PR interval of 160ms. Twenty-four hours later
her EKG showed a QTc interval of 457ms, PR interval of
170ms, and heart rate of 89 bpm (Figure 1). Of note, delta
waves were not appreciated on either EKG. Initially, the
patient was worked up for chest pain via 3 sets of troponins,
EKG, and stress test. All test results came back negative. Her
symptoms resolved within 24 hours with no changes in med-
ication, and the patient was discharged without further
issues.
3. Discussion
In recent years, special consideration has been placed on the
QTc prolonging side effects of various psychotropic medica-
tions, particularly, typical antipsychotics such as haloperidol
[7], droperidol [8], and atypical antipsychotics such as olan-
zapine, ziprasidone, and risperidone [9]. But very little is
known about the effects antipsychotics may have on patients
with WPW. We have recently reviewed all published infor-
mation currently available [10], which mostly comes from
case reports, some providing conflicting results. For example,
olanzapine has been shown to have varying levels of safety in
WPW patients. In one case a dosage of 5mg/day was shown
to cause QTc prolongation from 390 to 466ms [11]. In
another case, a dosage of 7.5mg/day was shown to have no
effect on QTc intervals [12]. On the other hand, data on ris-
peridone is more consistent. In two separate cases, risperi-
done at 1mg BID induced palpitations, QTc prolongation,
shortened PR intervals, and induction of a delta wave on
EKG [9, 13]. To our knowledge, there is no published data
on the effects of quetiapine on WPW.
Quetiapine is a dibenzothiazepine derivative that is FDA-
approved to treat schizophrenia and bipolar disorder. Com-
pared to typical antipsychotics, quetiapine is unique in that
it has transient antagonist effects on dopamine 2 receptors
and, as a result, lower risk for extrapyramidal symptoms
[14]. At the same time, when compared to typical antipsy-
chotics, quetiapine has an affinity for muscarinic receptors
resulting in anticholinergic side effects such as orthostatic
hypotension and transient sedation [15].
The general medical effects of quetiapine overdose have
been documented in several previous case studies. Most over-
dose cases result in exaggeration of the anticholinergic side
effects including tachycardia, hypotension, and sedation.
However, several other symptoms have been documented
in severe overdoses. One report in a 26-year-old woman
who ingested over 10,000mg of quetiapine, resulted in rapid
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Figure 1: Effects of quetiapine on QTc on a patient with Wolff-Parkinson-White (WPW) Syndrome. This graph represents changes in the
QTc interval expressed in milliseconds at various points in time including at baseline, 2, 24, and 48 hours postoverdose and then finally a
year after.
Table 1: EKG parameters at baseline and several time points after
quetiapine overdose.
QT QTc PR interval Pulse
Baseline 358ms 445ms 160ms 93 BPM
2-hour postintoxication 416ms 486ms 146ms 82 BPM
24-hour postintoxication 404ms 472ms 180ms 82 BPM
48-hour postintoxication 414ms 434ms 160ms 66 BPM
1-year postintoxication 344ms 450ms 170ms 89 BPM
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Another case was a 19-year-old man who ingested 9,600mg
of quetiapine, leading to QTc prolongation [17]. A third pub-
lication described a 31-year-old female who ingested
2,000mg of quetiapine and then became comatose requiring
intubation. QTc prolongation was also observed [5].
In our case, our patient had an overdose of 1,200mg that
resulted in typical anticholinergic side effects of hypotension
and sedation. Initially, the patient presented with concerning
symptoms of QTc prolongation. However, despite having an
extra electrical pathway, the patient did not develop any
further cardiac complications such as arrhythmia. In fact,
discontinuation of quetiapine led to recovery within 48
hours. Furthermore, after reintroduction of quetiapine to
therapeutic levels, the patient did not present any clinical
symptoms associated with WPW such as palpitations or
shortness of breath. The only symptoms that the patient
expressed were mild fatigue, which can be attributed to
the anticholinergic effects of quetiapine and mild QTc pro-
longation. Of note, the side effect of fatigue resolved after
slightly lowering her quetiapine dose. Her QT interval also
returned to baseline.
Most importantly, the patient was discharged on a thera-
peutic dose of quetiapine with no cardiac complications. This
was confirmed upon reevaluation 1 year after discharge in
which the patient initially reported some symptoms that
could be related to WPW.While the patient did report palpi-
tations, the EKG demonstrated a QTc interval similar to
baseline. A repeat EKG 24 hours later remained at baseline.
Thus, it is evident that 1 year of therapeutic dosage of quetia-
pine did not affect the patient’s WPW.
It also has to be considered that the patient was concom-
itantly taking trazodone and venlafaxine. While some studies
have shown a slight increase in QTc interval with trazodone
[18] and venlafaxine [19], this side effect is less frequently
observed than when quetiapine is administered. The combi-
nation of quetiapine with trazodone, especially considering
that the patient overdosed on 2000mg of trazodone, could
have elicited significant QTc prolongation and even Tor-
sades. Serious cardiac arrhythmias have been documented
in cases of trazodone and venlafaxine overdose or when com-
bined with other QTc prolonging medications [20].
In conclusion, to our knowledge, this is the first case
reporting the potential effects of quetiapine, trazodone, and
venlafaxine in an individual with WPW, and no serious car-
diac complications were encountered even after a year of
follow-up. But these medications cannot be considered
entirely safe for patients with WPW until further research
is developed on this topic.
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